Summit Therapeutics Files 2024 DEF 14A
Ticker: SMMT · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
TL;DR
Summit Therapeutics dropped its 2024 proxy statement detailing exec pay. Check it for Duggan & Zanganeh's compensation.
AI Summary
Summit Therapeutics Inc. filed a DEF 14A on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and board member information, including specific compensation elements for individuals like Duggan and Zanganeh. It also references equity awards granted during the fiscal year.
Why It Matters
This filing provides transparency into how Summit Therapeutics compensates its top executives and board members, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: low — This is a routine proxy statement filing detailing executive compensation and board matters, not indicating new financial risks.
Key Players & Entities
- Summit Therapeutics Inc. (company) — Filer of the DEF 14A
- Duggan (person) — Executive/Board Member mentioned in compensation details
- Zanganeh (person) — Executive/Board Member mentioned in compensation details
- 2024-12-31 (date) — Fiscal year end
- 20250429 (date) — Filing date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing by Summit Therapeutics Inc. is to provide information to shareholders regarding the company's annual meeting, including details on executive compensation, board of directors, and other corporate governance matters.
For which fiscal year is Summit Therapeutics providing compensation details?
Summit Therapeutics is providing compensation details for the fiscal year ending December 31, 2024.
Who are some of the individuals whose compensation is detailed in this filing?
The filing mentions individuals such as Duggan and Zanganeh in the context of executive compensation and equity awards.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 29, 2025.
What is the company's Standard Industrial Classification (SIC) code?
Summit Therapeutics Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 by Duggan regarding Summit Therapeutics Inc. (SMMT).